This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
The review covers several strategies for oral peptide delivery using lipid nanocarriers:
- Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) protect peptides from enzymatic degradation
- Absorption enhancers can be incorporated to improve gut membrane permeability
- PEGylation of nanocarriers improves stability and circulation time
- Lipidization (adding fatty acid chains to peptides) improves membrane interaction
Animal studies have shown significant hypoglycemic (blood sugar lowering) activity and safety for lipid nanocarrier-delivered insulin and GLP-1 agonists. However, translating these results to humans has been a persistent challenge.
The review also discusses the clinical status of various nanocarrier approaches for anti-diabetic peptides, noting that few have advanced to human trials.
Why it matters
Diabetes requires lifelong treatment, and most peptide-based therapies require injections. Making insulin and GLP-1 drugs available as pills would dramatically improve patient compliance and quality of life. Lipid nanocarriers are one of the most promising platforms for achieving this.
The numbers in context
SLNs, NLCs, liposomes; absorption enhancers, PEGylation, lipidization; animal hypoglycemic activity confirmed; few human trials
How the study worked
Narrative review of lipid nanocarrier technologies for oral delivery of insulin and GLP-1 receptor agonists, covering formulation strategies, absorption enhancement mechanisms, animal study results, and clinical development status.
Who was studied
Review of oral peptide delivery literature (no study population)
What this study cannot tell us
This is a review without new data. Most lipid nanocarrier work is in animal models, and human translation has been difficult. Manufacturing scalability and cost are not addressed. Regulatory pathways for nanomedicine-based oral peptides are complex and uncertain.
Read the original research
Role of lipid nanocarriers for enhancing oral absorption and bioavailability of insulin and GLP-1 receptor agonists.
Journal of drug targeting, 29(8), 834-847
Citation
Poudwal, Swapna; Misra, Ambikanandan; Shende, Pravin. (2021). Role of lipid nanocarriers for enhancing oral absorption and bioavailability of insulin and GLP-1 receptor agonists.. Journal of drug targeting, 29(8), 834-847. https://doi.org/10.1080/1061186X.2021.1894434